Literature DB >> 10715261

Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humans.

W J Hobbs1, S Fynn, D M Todd, P Wolfson, M Galloway, C J Garratt.   

Abstract

BACKGROUND: Although atrial electrical remodeling has been studied extensively in animal models, the reversibility of this phenomenon after termination of clinical atrial fibrillation (AF) has not been demonstrated. We aimed to examine this important question of reversibility by using AF cycle length (AFCL) and coupling intervals of atrial premature beats after cardioversion as measures of atrial refractoriness. METHODS AND
RESULTS: We measured AFCL at the right atrial appendage and distal coronary sinus before attempting internal cardioversion in 39 patients with persistent AF. Patients were monitored by daily transtelephonic recordings after discharge and admitted rapidly for repeat internal cardioversion if there was spontaneous AF recurrence. Measurements of AFCL were repeated immediately before repeat cardioversions in the 17 patients who had recurrence of AF. There was an increase in AFCL from the initial cardioversion to that measured at the time of first AF recurrence at both the right atrial appendage (161+/-22 vs 167+/-26 ms, P=0.05) and distal coronary sinus (162+/-20 vs 168+/-22 ms, P=0.01) sites. The magnitude of increase in AFCL was positively correlated with duration of sinus rhythm before AF recurrence (r=0.524, P=0.001). Other measures of refractoriness (shortest coupling interval of atrial premature beats and directly measured refractory periods after cardioversion) also increased from initial to subsequent cardioversions.
CONCLUSIONS: These findings demonstrate that changes in atrial electrophysiology associated with chronic AF in humans are reversible after cardioversion and that the extent of this reversal is dependent on the duration of sinus rhythm after cardioversion.

Entities:  

Mesh:

Year:  2000        PMID: 10715261     DOI: 10.1161/01.cir.101.10.1145

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

Review 1.  Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.

Authors:  Sean T Duggan; Lesley J Scott
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Internal defibrillation: where we have been and where we should be going?

Authors:  Samuel Lévy
Journal:  J Interv Card Electrophysiol       Date:  2005-08       Impact factor: 1.900

3.  Characteristic changes of volume and three-dimensional structure of the left atrium in different forms of atrial fibrillation: predictive value after ablative treatment.

Authors:  Sotirios Nedios; Min Tang; Mattias Roser; Natalia Solowjowa; Jin-Hong Gerds-Li; Eckart Fleck; Charalampos Kriatselis
Journal:  J Interv Card Electrophysiol       Date:  2011-06-11       Impact factor: 1.900

Review 4.  Early Cardioversion in Atrial Fibrillation: Earlier Is Better, but Not Always and (Maybe) Not Immediately.

Authors:  Paloma G Piña; Alexandru B Chicos
Journal:  Curr Atheroscler Rep       Date:  2017-01       Impact factor: 5.113

5.  Exponential distribution of long heart beat intervals during atrial fibrillation and their relevance for white noise behaviour in power spectrum.

Authors:  Thomas Hennig; Philipp Maass; Junichiro Hayano; Stefan Heinrichs
Journal:  J Biol Phys       Date:  2006-12-15       Impact factor: 1.365

6.  Pulmonary vein ablation for idiopathic atrial fibrillation: six month outcome of first procedure in 100 consecutive patients.

Authors:  J P Bourke; A Dunuwille; D O'Donnell; S Jamieson; S S Furniss
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

7.  Restoring normal sinus rhythm in atrial fibrillation : evidence from pharmacologic therapy and catheter ablation trials.

Authors:  Peter Zimetbaum
Journal:  Curr Cardiol Rep       Date:  2006-09       Impact factor: 2.931

8.  Sinus bradycardia and sinus pauses immediately after electrical cardioversion of persistent atrial fibrillation--what do they mean?

Authors:  Dritan Poçi; Britt-Marie Abrahamsson; Nils Edvardsson; Lennart Bergfeldt
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-01-20       Impact factor: 1.468

Review 9.  Evolving concepts in the treatment of atrial fibrillation.

Authors:  Parimal B Maniar; Jonathan S Steinberg
Journal:  Curr Cardiol Rep       Date:  2003-09       Impact factor: 2.931

Review 10.  Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.

Authors:  Gerald V Naccarelli; Frank Peacock
Journal:  Vasc Health Risk Manag       Date:  2009-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.